Designing vaccines for the twenty-first century society

Frontiers in Immunology

Volumn 5, Issue JAN, 2014, Pages

  Finco, Oretta ^a   Rappuoli, Rino ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Glyco conjugate; Structural vaccinology; Technologies; Vaccination; Vaccine design

Indexed keywords

B LYMPHOCYTE RECEPTOR; DIPHTHERIA TOXOID CRM197; GLYCOCONJUGATE; HEMAGGLUTININ; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A; POLYSACCHARIDE; SIALIDASE; TETANUS TOXOID; VACCINE;

BIOINFORMATICS; CD8+ T LYMPHOCYTE; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL (TOPIC); DRUG DESIGN; GENE SEQUENCE; GENE TARGETING; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; INFECTION; MORTALITY; NEISSERIA MENINGITIDIS; NONHUMAN; SHORT SURVEY; TECHNOLOGY; VACCINATION;

EID: 84895536237     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00012     Document Type: Short Survey

References (68)

1. Willis NJ. Edward Jenner and the eradication of smallpox. Scott Med J (1997) 42:118-21.
2. Lakhani S. Early clinical pathologists: Edward Jenner (1749-1823). J Clin Pathol (1992) 45:756-8. doi:10.1136/jcp.45.9.756.
3. Kaushik DK, Sehgal D. Developing antibacterial vaccines in genomics and proteomics era. Scand J Immunol (2008) 67:544-52. doi:10.1111/j.1365-3083.2008.02107.x.
4. Rappuoli R, Miller HI, Falkow S. Medicine. The intangible value of vaccination. Science (2002) 297:937-9. doi:10.1126/science.1075173.
5. Plotkin SA. Vaccines: past, present and future. Nat Med (2005) 11:S5-11. doi:10.1038/nm1209.
6. Rappuoli R. From Pasteur to genomics: progress and challenges in infectious diseases. Nat Med (2004) 10:1177-85. doi:10.1038/nm1129.
7. Makela PH, Peltola H, Kayhty H, Jousimies H, Pettay O, Ruoslahti E, et al. Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis (1977) 136(Suppl):S43-50. doi:10.1093/infdis/136.Supplement.S43.
8. Peltola H, Makela H, Kayhty H, Jousimies H, Herva E, Hallstrom K, et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med (1977) 297:686-91. doi:10.1056/NEJM197709292971302.
9. Lesinski GB, Westerink MA. Novel vaccine strategies to T-independent antigens. J Microbiol Methods (2001) 47:135-49. doi:10.1016/S0167-7012(01)00290-1.
10. Conaty S, Watson L, Dinnes J, Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine (2004) 22:3214-24. doi:10.1016/j.vaccine.2003.08.050.
11. Lepow ML, Goldschneider I, Gold R, Randolph M, Gotschlich EC. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics (1977) 60:673-80.
12. Peltola H, Kayhty H, Virtanen M, Makela PH. Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med (1984) 310:1561-6. doi:10.1056/NEJM198406143102404.
13. Makela PH, Kayhty H. Evolution of conjugate vaccines. Expert Rev Vaccines (2002) 1:399-410. doi:10.1586/14760584.1.3.399.
14. Lai Z, Schreiber JR. Antigen processing of glycoconjugate vaccines; the polysaccharide portion of the pneumococcal CRM(197) conjugate vaccine co-localizes with MHC II on the antigen processing cell surface. Vaccine (2009) 27:3137-44. doi:10.1016/j.vaccine.2009.03.064.
15. Smith KG, Light A, Nossal GJ, Tarlinton DM. The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary immune response. EMBO J (1997) 16:2996-3006. doi:10.1093/emboj/16.11.2996.
16. Avci FY, Kasper DL. How bacterial carbohydrates influence the adaptive immune system. Annu Rev Immunol (2010) 28:107-30. doi:10.1146/annurev-immunol-030409-101159.
17. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol (2009) 9:213-20. doi:10.1038/nri2494.
18. Black SB, Shinefield HR, Hiatt RA, Fireman BH. Efficacy of Haemophilus influenzae type b capsular polysaccharide vaccine. Pediatr Infect Dis J (1988) 7:149-56. doi:10.1097/00006454-198803000-00003.
19. Eskola J, Peltola H, Takala AK, Kayhty H, Hakulinen M, Karanko V, et al. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. N Engl J Med (1987) 317:717-22. doi:10.1056/NEJM198709173171201.
20. Schneerson R, Barrera O, Sutton A, Robbins JB. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med (1980) 152:361-76. doi:10.1084/jem.152.2.361.
21. Costantino P, Norelli F, Giannozzi A, D'Ascenzi S, Bartoloni A, Kaur S, et al. Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines. Vaccine (1999) 17:1251-63. doi:10.1016/S0264-410X(98)00348-X.
22. Lakshman R, Finn A. Meningococcal serogroup C conjugate vaccine. Expert Opin Biol Ther (2002) 2:87-96. doi:10.1517/14712598.2.1.87.
23. Black S, Klein NP, Shah J, Bedell L, Karsten A, Dull PM. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine (2010) 28:657-63. doi:10.1016/j.vaccine.2009.10.104.
24. Heath PT, McVernon J. The UK Hib vaccine experience. Arch Dis Child (2002) 86:396-9. doi:10.1136/adc.86.6.396.
25. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis (2003) 188:481-5. doi:10.1086/376997.
26. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine (2009) 27(Suppl 2):B51-63. doi:10.1016/j.vaccine.2009.04.063.
27. Lo H, Tang CM, Exley RM. Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect Dis (2009) 9:418-27. doi:10.1016/S1473-3099(09)70132-X.
28. Stephens DS. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine (2009) 27(Suppl 2):B71-7. doi:10.1016/j.vaccine.2009.04.070.
29. Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science (1995) 269:496-512. doi:10.1126/science.7542800.
30. Tettelin H, Saunders NJ, Heidelberg J, Jeffries AC, Nelson KE, Eisen JA, et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science (2000) 287:1809-15. doi:10.1126/science.287.5459.1809.
31. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science (2000) 287:1816-20. doi:10.1126/science.287.5459.1816.
32. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, Santini L, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A (2006) 103:10834-9. doi:10.1073/pnas.0603940103.
33. Barocchi MA, Ries J, Zogaj X, Hemsley C, Albiger B, Kanth A, et al. A pneumococcal pilus influences virulence and host inflammatory responses. Proc Natl Acad Sci U S A (2006) 103:2857-62. doi:10.1073/pnas.0511017103.
34. Gianfaldoni C, Censini S, Hilleringmann M, Moschioni M, Facciotti C, Pansegrau W, et al. Streptococcus pneumoniae pilus subunits protect mice against lethal challenge. Infect Immun (2007) 75:1059-62. doi:10.1128/IAI.01400-06.
35. Mora M, Bensi G, Capo S, Falugi F, Zingaretti C, Manetti AG, et al. Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens. Proc Natl Acad Sci U S A (2005) 102:15641-6. doi:10.1073/pnas.0507808102.
36. Montigiani S, Falugi F, Scarselli M, Finco O, Petracca R, Galli G, et al. Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun (2002) 70:368-79. doi:10.1128/IAI.70.1.368-379.2002.
37. Finco O, Frigimelica E, Buricchi F, Petracca R, Galli G, Faenzi E, et al. Approach to discover T-and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines. Proc Natl Acad Sci U S A (2011) 108:9969-74. doi:10.1073/pnas.1101756108.
38. Maione D, Margarit I, Rinaudo CD, Masignani V, Mora M, Scarselli M, et al. Identification of a universal Group B Streptococcus vaccine by multiple genome screen. Science (2005) 309:148-50. doi:10.1126/science.1109869.
39. Moriel DG, Bertoldi I, Spagnuolo A, Marchi S, Rosini R, Nesta B, et al. Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci U S A (2010) 107:9072-7. doi:10.1073/pnas.0915077107.
40. Metzker ML. Sequencing technologies-the next generation. Nat Rev Genet (2010) 11:31-46. doi:10.1038/nrg2626.
41. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine (2001) 19:2688-91. doi:10.1016/S0264-410X(00)00554-5.
42. Scarselli M, Arico B, Brunelli B, Savino S, Di MF, Palumbo E, et al. Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med (2011) 3:91ra62. doi:10.1126/scitranslmed.3002234.
43. DeKosky BJ, Ippolito GC, Deschner RP, Lavinder JJ, Wine Y, Rawlings BM, et al. High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire. Nat Biotechnol (2013) 31:166-9. doi:10.1038/nbt.2492.
44. Wilson PC, Andrews SF. Tools to therapeutically harness the human antibody response. Nat Rev Immunol (2012) 12:709-19. doi:10.1038/nri3285.
45. -1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 333:1593-602. doi:10.1126/science.1207532.
46. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science (2013) 342:592-8. doi:10.1126/science.1243283.
47. Barh D, Misra AN, Kumar A, Vasco A. A novel strategy of epitope design in Neisseria gonorrhoeae. Bioinformation (2010) 5:77-85. doi:10.6026/97320630005077.
48. Dormitzer PR, Ulmer JB, Rappuoli R. Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol (2008) 26:659-67. doi:10.1016/j.tibtech.2008.08.002.
49. Dormitzer PR, Grandi G, Rappuoli R. Structural vaccinology starts to deliver. Nat Rev Microbiol (2012) 10:807-13. doi:10.1038/nrmicro2893.
50. Adkins B, Leclerc C, Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat Rev Immunol (2004) 4:553-64. doi:10.1038/nri1394.
51. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol (2009) 9:185-94. doi:10.1038/nri2508.
52. Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine (2009) 27:6291-5. doi:10.1016/j.vaccine.2009.02.004.
53. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J (2009) 28:563-71. doi:10.1097/INF.0b013e31819d6394.
54. Qureshi N, Takayama K, Ribi E. Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J Biol Chem (1982) 257:11808-15.
55. Giannini SL, Hanon E, Moris P, Van MM, Morel S, Dessy F, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine (2006) 24:5937-49. doi:10.1016/j.vaccine.2006.06.005.
56. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 191:654-65. doi:10.1086/428404.
57. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van GF, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 194:1661-71. doi:10.1086/508748.
58. Johnston MI, Fauci AS. An HIV vaccine-evolving concepts. N Engl J Med (2007) 356:2073-81. doi:10.1056/NEJMra066267.
59. Cohen J. AIDS research. Promising AIDS vaccine's failure leaves field reeling. Science (2007) 318:28-9. doi:10.1126/science.318.5847.28.
60. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA vaccines: current progress. Clin Infect Dis (2011) 53:296-302. doi:10.1093/cid/cir334.
61. Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 23:421-9. doi:10.1016/j.coi.2011.03.008.
62. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science (1990) 247:1465-8. doi:10.1126/science.1690918.
63. Martinon F, Krishnan S, Lenzen G, Magne R, Gomard E, Guillet JG, et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol (1993) 23:1719-22. doi:10.1002/eji.1830230749.
64. Probst J, Weide B, Scheel B, Pichler BJ, Hoerr I, Rammensee HG, et al. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther (2007) 14:1175-80. doi:10.1038/sj.gt.3302964.
65. Kreiter S, Diken M, Selmi A, Tureci O, Sahin U. Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol (2011) 23:399-406. doi:10.1016/j.coi.2011.03.007.
66. Bernstein DI, Reap EA, Katen K, Watson A, Smith K, Norberg P, et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine (2009) 28:484-93. doi:10.1016/j.vaccine.2009.09.135.
67. Dormitzer PR, Suphaphiphat P, Gibson DG, Wentworth DE, Stockwell TB, Algire MA, et al. Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med (2013) 5:185ra68. doi:10.1126/scitranslmed.3006368.
68. Rappuoli R, Mandl CW, Black S, De Gregorio E. Vaccines for the twenty-first century society. Nat Rev Immunol (2011) 11(12):865-72. doi:10.1038/nri3085.